Literature DB >> 12075397

Downregulation of immunodetectable atrial connexin40 in a canine model of chronic left ventricular myocardial infarction: implications to atrial fibrillation.

Keiko Ohara1, Yasushi Miyauchi, Toshihiko Ohara, Michael C Fishbein, Shengmei Zhou, Moon-Hyoung Lee, William J Mandel, Peng-Sheng Chen, Hrayr S Karagueuzian.   

Abstract

BACKGROUND: The substrate(s) for atrial fibrillation associated with chronic left ventricular myocardial infarction remain poorly defined. Since atrial connexin40 has a rapid turnover rate and may cause atrial fibrillation, we hypothesized that chronic left ventricular myocardial infarction downregulates atrial Connexin40 and increases atrial fibrillation vulnerability. METHODS AND
RESULTS: The left anterior descending coronary artery was occluded distal to the first diagonal branch in five dogs and studied 7 weeks later. Five dogs with no left anterior descending coronary artery occlusion served as control. Vulnerability to atrial fibrillation was tested by burst atrial stimulation (50 milliseconds for 3 seconds). Atrial fibrillation was induced in all myocardial infarction dogs, lasting from 20 seconds to several minutes. In contrast, only rapid repetitive activity and short-lasting atrial fibrillation (< 5 seconds) could be induced in control dogs. The mean refractory periods of epicardial RA and LA appendages were not significantly different in the two groups. Mean left ventricular myocardial infarction size was 17 +/- 4% of the left ventricle. Histologic analyses showed no signs of atrial ischemic injury or interstitial fibrosis in either group. Atrial myocyte diameter measured at the level of the nuclei of longitudinally sectioned myocytes was not significantly different in the two groups (10.1 +/- 1.2 microm vs. 10.2 +/- 1.2 microm; P = 0.3). Atrial Connexin40 (both left and right atria) in the left ventricular myocardial infarction group was highly heterogeneous and had significantly smaller total area stained than in the control (0.48 +/- 0.09% vs. 0.82 +/- 0.13%; P < 0.01).
CONCLUSIONS: Chronic left ventricular myocardial infarction downregulates immunodetectable atrial Connexin40, a property that might contribute to the increased atrial fibrillation vulnerability in this model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075397     DOI: 10.1177/107424840200700205

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  6 in total

1.  Glycolytic inhibition causes spontaneous ventricular fibrillation in aged hearts.

Authors:  Norishige Morita; Jong-Hwan Lee; Aneesh Bapat; Michael C Fishbein; William J Mandel; Peng-Sheng Chen; James N Weiss; Hrayr S Karagueuzian
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-08       Impact factor: 4.733

2.  Association of atrial fibrillation with gene polymorphisms of connexin 40 and angiotensin II receptor type 1 in Chongming adults of Shanghai.

Authors:  Shuxin Hou; Yingmin Lu; Damin Huang; Xiaohan Luo; Dongmei Yue; Jinchun Zhang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Pulmonary venous structural remodeling in a canine model of chronic atrial dilation due to mitral regurgitation.

Authors:  Qi Sun; Min Tang; Jielin Pu; Shu Zhang
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

Review 4.  Redox regulation, NF-kappaB, and atrial fibrillation.

Authors:  Ge Gao; Samuel C Dudley
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 5.  Animal models of arrhythmia: classic electrophysiology to genetically modified large animals.

Authors:  Sebastian Clauss; Christina Bleyer; Dominik Schüttler; Philipp Tomsits; Simone Renner; Nikolai Klymiuk; Reza Wakili; Steffen Massberg; Eckhard Wolf; Stefan Kääb
Journal:  Nat Rev Cardiol       Date:  2019-08       Impact factor: 32.419

Review 6.  The canine chronic atrioventricular block model in cardiovascular preclinical drug research.

Authors:  Vera Loen; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2021-05-04       Impact factor: 9.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.